



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/016,868	12/14/2001	Paul Seelinger	1274-002	6000

7590 05/06/2004

Kenneth F. Florek, Esq.
HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036

EXAMINER

CHOJNACKI, MELLISSA M

ART UNIT	PAPER NUMBER
----------	--------------

2175

DATE MAILED: 05/06/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/016,868

Applicant(s)

SEELINGER, PAUL

Examiner

Mellissa M Chojnacki

Art Unit

2175

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-18 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. ____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.



SAM RIMELL
PRIMARY EXAMINER

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 2.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: ____.

Specification

1. The arrangement of the disclosed application does not conform with 37 CFR 1.77(b).

Section headings are underlined and boldface throughout the disclosed specification.

Section headings should not be underlined and/or **boldfaced**. Appropriate corrections are required according to the guidelines provided below:

2. The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC (See 37 CFR 1.52(e)(5) and MPEP 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text are permitted to be submitted on compact discs.) or
REFERENCE TO A "MICROFICHE APPENDIX" (See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.)
- (e) BACKGROUND OF THE INVENTION.
 - (1) Field of the Invention.
 - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (f) BRIEF SUMMARY OF THE INVENTION.
- (g) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (h) DETAILED DESCRIPTION OF THE INVENTION.

Art Unit: 2175

- (i) CLAIM OR CLAIMS (commencing on a separate sheet).
- (j) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (k) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claims 1, 3-5, 7-11 and 14-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Mayaud (U.S. Patent No. 5,845,255).

As to claim 1, Mayaud teaches a secure, Internet-based universal data repository system for medical product information (See column 48, lines 52-60, where "repository" is read on "data warehouse"), the system comprising

a) a database containing medical product information (See abstract; column 5, lines 48; column 47, lines 47-53) comprising one or more of the following fields or combinations of fields:

- i) specially defined and formatted product descriptions, including NDC numbers;
- ii) safety codes;
- iii) product scan codes;

Art Unit: 2175

- iv) product recall information (See column 33, lines 29-34); and
- v) product equivalency information (See column 4, lines 56-65)
- vi) optionally, company specific product information for specific technology products (See column 53, lines 13-22); and
- b) a user access data auditor which provides a user data access audit trail (See column 15, lines 42-45);
- c) a programmed system computer for processing and storing the medical product information (See column 31, lines 39-49);
- d) an input device operatively interconnected to the programmed system computer means (See column 7, lines 62-67); and
- e) an output device operatively interconnected to the programmed system computer means (See column 55, lines 15-17).

As to claim 3, Mayaud teaches where the user access data auditor strictly controls access to Internet-based data tables by user type and privilege, and wherein the auditor logs when a user views a recall message, thereby tracking whether the recall message has been viewed (See column 15, lines 42-45; column 16, lines 1-5; column 17, lines 60-67; column 18, lines 1-5).

As to claim 4, Mayaud teaches comprising an updating and maintaining (See column 14, lines 32-37; column 14, lines 66-67; column 15, lines 1-6; lines 20-25)

Art Unit: 2175

means for the medical product information via Internet communication by accessing a dedicated web site (URL) using web browsers (See column 48, lines 1-7).

As to claim 5, Mayaud teaches wherein the input and output devices comprise a computer display screen having the medical product information displayed in fields (See column 6, lines 37-57; also see Fig. 1-14).

As to claim 7, Mayaud teaches further comprising a voice recognition unit for permitting the user to communicate with the system by verbal inputs (See column 9, lines 17-23; column 10, lines 3-8).

As to claim 8, Mayaud teaches wherein the input device cooperates with the voice recognition unit (See column 9, lines 17-23; column 10, lines 3-8).

As to claim 9, Mayaud teaches wherein the input means further comprises a pen interface for permitting a user to communicate with the system by writing on a screen with a pen (See column 7, lines 44-56).

As to claim 10, Mayaud teaches wherein the information is received by at least one output device taken from the group consisting of voice, a keyboard, a pen and a mouse (See column 7, lines 44-56, column 9, lines 17-23; column 10, lines 3-8; column 55, lines 15-17).

Art Unit: 2175

As to claim 11, Mayaud, teaches wherein the medical product is taken from the group consisting of manufactured generic, brand, over-the-counter, biologicals, blood products, medical devices, and intravenous solutions (See column 4, lines 56-65; column 26, lines 21-25; column 29, lines 47-50).

As to claim 14, Mayaud teaches a method of creating and using product recall information, the method comprising the steps of:

- a. accessing product recall information for manufactured products (See abstract; column 1, lines 12-19; column 33, lines 29-34);
- b. creating at least one product recall database (See abstract; column 5, lines 44-48; column 47, lines 47-53; column 33, lines 29-34);
- c. updating product recall data in real time (See column 5, lines 44-48; column 14, lines 66-67; column 15, lines 1-6; column 33, lines 29-34); and
- e. disseminating product recall information in real time or on a designated schedule via the Internet to institutionally-based local data repositories that support and use medication safety systems at healthcare institutions (See column 5, lines 44-48; column 14, lines 66-67; column 15, lines 1-6; column 33, lines 29-34).

As to claim 15, Mayaud teaches wherein the at least one product recall database additionally stores previously known product recall data associated with the product (See abstract; column 5, lines 44-48; column 47, lines 47-53; column 33, lines 29-34).

Art Unit: 2175

As to claim 16, Mayaud teaches further comprising means for receiving and storing messages relating to product recalls, the messages being automatically displayed to a user upon the identification of the user (See column 23, lines 19-39; column 33, lines 29-34).

As to claim 17, Mayaud teaches further comprising means for receiving and storing messages relating to product recalls, the messages consisting of data comprising at least one of the items selected from the following: identification of the product, lot numbers recalled, reasons for recall, and severity of recall (See column 23, lines 19-39; column 33, lines 29-34).

As to claim 18, Mayaud teaches further comprising means operable to use the medical product database and patient specific information to calculate a dosage recommendation, including an amount and a frequency of administration of the medical product (See column 4, lines 30-41; column 5, lines 25-32).

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 2, 6 and 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mayaud (U.S. Patent No. 5,845,255) in view of Portwood et al. (U.S. Patent No. 6,305,377).

As to claim 2, Mayaud does not teach wherein the product scan codes include at least one medication identifier and information comprising at least one of the items selected from the group consisting of: NDC number, GTIN number and UPC Code.

Portwood et al. teaches a system and method for improving compliance of a medical regimen (See abstract), in which he teaches wherein the product scan codes include at least one medication identifier and information comprising at least one of the items selected from the group consisting of: NDC number, GTIN number and UPC Code (See column 1, lines 53-57; column 8, lines 18-26).

Therefore, it would have been obvious to a person having ordinary skill in the art at the time of the invention was made to have modified Mayaud, to include wherein the product scan codes include at least one medication identifier and information comprising at least one of the items selected from the group consisting of: NDC number, GTIN number and UPC Code.

It would have been obvious to a person having ordinary skill in the art at the time the invention was made to have modified Mayaud, by the teachings of Portwood et al. because wherein the product scan codes include at least one medication identifier and information comprising at least one of the items selected from the group consisting of:

NDC number, GTIN number and UPC Code would improve checking procedures to determine if a prescription complies with a recommended regimen (See Portwood et al., column 1, lines 51-57).

As to claim 6, Mayaud still does not teach further comprising scan codes for medications in the database.

Portwood et al., teaches further comprising scan codes for medications in the database (See column 1, lines 53-57; column 8, lines 18-26).

Therefore, it would have been obvious to a person having ordinary skill in the art at the time of the invention was made to have modified Mayaud, to include further comprising scan codes for medications in the database.

It would have been obvious to a person having ordinary skill in the art at the time the invention was made to have modified Mayaud, by the teachings of Portwood et al. because further comprising scan codes for medications in the database. would improve checking procedures to determine if a prescription complies with a recommended regimen (See Portwood et al., column 1, lines 51-57).

As to claim 12, Mayaud teaches a method for creating and using product data, the method comprising the steps of:

b. creating at least one product identification and description database (See abstract; column 5, lines 44-48; column 47, lines 47-53);

c. updating product specific data in real time (See column 5, lines 44-48; column 14, lines 66-67; column 15, lines 1-6); and

d. disseminating product information and recall information in real time or on a designated schedule via the Internet to institutionally-based local data repositories that support and use medication safety systems at healthcare institutions (See column 5, lines 44-48; column 14, lines 66-67; column 15, lines 1-6; column 33, lines 29-34).

Mayaud does not teach accessing product scan code information for manufactured products.

Portwood et al., teaches a system and method for improving compliance of a medical regimen (See abstract), in which he teaches accessing product scan code information for manufactured products (See column 1, lines 53-57; column 8, lines 18-26).

Therefore, it would have been obvious to a person having ordinary skill in the art at the time of the invention was made to have modified Mayaud, to include accessing product scan code information for manufactured products.

It would have been obvious to a person having ordinary skill in the art at the time the invention was made to have modified Mayaud, by the teachings of Portwood et al., because accessing product scan code information for manufactured products would create a faster and more efficient way of accessing product information in a database.

As to claim 13, Mayaud as modified, teaches comprising retrieving product information across a network or the Internet from a remote source database and

Art Unit: 2175

displaying or otherwise using retrieved product information in real time (See Mayaud, column 5, lines 44-48; column 14, lines 66-67; column 15, lines 1-6; column 48, lines 1-7).

Conclusion

7. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

The following patents are cited to further show the state of the art with respect to universal medication scan code data repository in general:

U.S. Patent No. 5,859,972 to Subramaniam et al., for disclosing multiple server repository and multiple server remote application virtual client computer.

U.S. Patent No. 5,974,396 to Anderson et al., for disclosing a method and system for gathering and analyzing consumer purchasing information based on product and consumer clustering relationships.

U.S. Patent No. 6,219,674 to Classen., for disclosing a system for creating and managing proprietary product data.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mellissa M. Chojnacki whose telephone number is 730-305-8769. The examiner can normally be reached on 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dov Popovici can be reached on 703-305-3830. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mmc
April 15, 2004



SAM RIMELL
PRIMARY EXAMINER